UBS Group
ODT

UBS Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

UBS Group’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-299
Closed – – 11597
2021
Q4 		$0 Buy
+299
New +$707 ﹤0.01% 11234
2021
Q3 		– Sell
-6,033
Closed -$21K – 10608
2021
Q2 		$21K Sell
6,033
-75
-1% -$257 ﹤0.01% 7304
2021
Q1 		$21K Buy
6,108
+5,679
+1,324% +$107K ﹤0.01% 7364
2020
Q4 		$9K Sell
429
-4,682
-92% -$72.3K ﹤0.01% 7595
2020
Q3 		$69K Sell
5,111
-1,565
-23% -$44.3K ﹤0.01% 5425
2020
Q2 		$283K Sell
6,676
-1,598
-19% -$51.7K ﹤0.01% 4553
2020
Q1 		$228K Sell
8,274
-8,826
-52% -$257K ﹤0.01% 4623
2019
Q4 		$555K Buy
17,100
+6,915
+68% +$214K ﹤0.01% 4750
2019
Q3 		$265K Buy
10,185
+8,434
+482% +$282K ﹤0.01% 5034
2019
Q2 		$64K Buy
1,751
+1,238
+241% +$29.7K ﹤0.01% 5709
2019
Q1 		$11K Sell
513
-2,354
-82% -$41.2K ﹤0.01% 6779
2018
Q4 		$40K Buy
2,867
+1,236
+76% +$19.2K ﹤0.01% 6292
2018
Q3 		$32K Buy
1,631
+766
+89% +$15.6K ﹤0.01% 6495
2018
Q2 		$19K Buy
+865
New +$20.2K ﹤0.01% 6748

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

UBS Group's ODT Position: Q1 2022 in Review

UBS Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 299 shares.

UBS Group first reported a position in ODT in Q2 2018 and held it in 14 quarters. The position peaked at $555K in Q4 2019. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • UBS Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • UBS Group sold 299 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022.
  • UBS Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2018 and held it in 14 quarters.
  • UBS Group's Odonate Therapeutics, Inc. Common Stock position peaked at $555K in Q4 2019.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.